Original Source(s)
Related Content
FDA Clears Golimumab Biosimilars
New biosimilars enter the market with pharmacy-level substitution eligibility for rheumatology and gastroenterology indications.
May 18, 2026
-
2 min
Healthcare utilization and costs in patients with rheumatoid arthritis using biologics or tofacitinib: a nationwide, population-based study
by Yen-Ju Chen, Wei-Li Ho, Hsian-Min Chen, Yi-Ming Chen, Hsin-Hua Chen
June 22, 2026
Reproductive Health Framework for Care
Narrative review and commentary proposes framework to address care gaps beyond disease control
April 13, 2026
-
4 min